Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07897227) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.' on Oct. 20.

Brief Summary: This study is a multicenter, open-label, dose-escalation, PK expansion, and cohort expansion, first-in-human phase I/II study to evaluate the safety, tolerability, PK profile, and preliminary antitumor efficacy of SYS6062, a CEACAM5-targeted antibody-conjugate drug, in patients with advanced solid tumors.

Study Start Date: Nov. 01

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors Gastric Cancer (GC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC)

Int...